349 related articles for article (PubMed ID: 25218194)
1. The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.
Kagina BM; Tameris MD; Geldenhuys H; Hatherill M; Abel B; Hussey GD; Scriba TJ; Mahomed H; Sadoff JC; Hanekom WA; ; Mansoor N; Hughes J; de Kock M; Whatney W; Africa H; Krohn C; Veldsman A; Kany AL; Douoguih M; Pau MG; Hendriks J; McClainc B; Benko J; Snowden MA; Hokey DA
Vaccine; 2014 Oct; 32(45):5908-17. PubMed ID: 25218194
[TBL] [Abstract][Full Text] [Related]
2. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.
Tameris M; Hokey DA; Nduba V; Sacarlal J; Laher F; Kiringa G; Gondo K; Lazarus EM; Gray GE; Nachman S; Mahomed H; Downing K; Abel B; Scriba TJ; McClain JB; Pau MG; Hendriks J; Dheenadhayalan V; Ishmukhamedov S; Luabeya AK; Geldenhuys H; Shepherd B; Blatner G; Cardenas V; Walker R; Hanekom WA; Sadoff J; Douoguih M; Barker L; Hatherill M
Vaccine; 2015 Jun; 33(25):2944-54. PubMed ID: 25936724
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(®)-TB Gold (+) Kenyan adults without evidence of tuberculosis.
Walsh DS; Owira V; Polhemus M; Otieno L; Andagalu B; Ogutu B; Waitumbi J; Hawkridge A; Shepherd B; Pau MG; Sadoff J; Douoguih M; McClain JB;
Vaccine; 2016 May; 34(21):2430-2436. PubMed ID: 27026148
[TBL] [Abstract][Full Text] [Related]
5. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.
Abel B; Tameris M; Mansoor N; Gelderbloem S; Hughes J; Abrahams D; Makhethe L; Erasmus M; de Kock M; van der Merwe L; Hawkridge A; Veldsman A; Hatherill M; Schirru G; Pau MG; Hendriks J; Weverling GJ; Goudsmit J; Sizemore D; McClain JB; Goetz M; Gearhart J; Mahomed H; Hussey GD; Sadoff JC; Hanekom WA
Am J Respir Crit Care Med; 2010 Jun; 181(12):1407-17. PubMed ID: 20167847
[TBL] [Abstract][Full Text] [Related]
6. A 2-Dose AERAS-402 Regimen Boosts CD8
Sivakumaran D; Blatner G; Bakken R; Hokey D; Ritz C; Jenum S; Grewal HMS
Front Immunol; 2021; 12():673532. PubMed ID: 34177914
[TBL] [Abstract][Full Text] [Related]
7. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
Sheehan S; Harris SA; Satti I; Hokey DA; Dheenadhayalan V; Stockdale L; Manjaly Thomas ZR; Minhinnick A; Wilkie M; Vermaak S; Meyer J; O'Shea MK; Pau MG; Versteege I; Douoguih M; Hendriks J; Sadoff J; Landry B; Moss P; McShane H
PLoS One; 2015; 10(11):e0141687. PubMed ID: 26529238
[TBL] [Abstract][Full Text] [Related]
8. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Tameris M; Mearns H; Penn-Nicholson A; Gregg Y; Bilek N; Mabwe S; Geldenhuys H; Shenje J; Luabeya AKK; Murillo I; Doce J; Aguilo N; Marinova D; Puentes E; Rodríguez E; Gonzalo-Asensio J; Fritzell B; Thole J; Martin C; Scriba TJ; Hatherill M;
Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
[TBL] [Abstract][Full Text] [Related]
11. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.
Nemes E; Hesseling AC; Tameris M; Mauff K; Downing K; Mulenga H; Rose P; van der Zalm M; Mbaba S; Van As D; Hanekom WA; Walzl G; Scriba TJ; McShane H; Hatherill M;
Clin Infect Dis; 2018 Feb; 66(4):554-563. PubMed ID: 29028973
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Mauff K; Hughes EJ; Moyo S; Brittain N; Lawrie A; Mulenga H; de Kock M; Gelderbloem S; Veldsman A; Hatherill M; Geldenhuys H; Hill AV; Hussey GD; Mahomed H; Hanekom WA; McShane H
J Infect Dis; 2011 Jun; 203(12):1832-43. PubMed ID: 21606542
[TBL] [Abstract][Full Text] [Related]
13. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study.
Spertini F; Audran R; Lurati F; Ofori-Anyinam O; Zysset F; Vandepapelière P; Moris P; Demoitié MA; Mettens P; Vinals C; Vastiau I; Jongert E; Cohen J; Ballou WR
Tuberculosis (Edinb); 2013 Mar; 93(2):179-88. PubMed ID: 23219236
[TBL] [Abstract][Full Text] [Related]
14. Attrition of T-cell functions and simultaneous upregulation of inhibitory markers correspond with the waning of BCG-induced protection against tuberculosis in mice.
Nandakumar S; Kannanganat S; Posey JE; Amara RR; Sable SB
PLoS One; 2014; 9(11):e113951. PubMed ID: 25419982
[TBL] [Abstract][Full Text] [Related]
15. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M; Satti I; Minhinnick A; Harris S; Riste M; Ramon RL; Sheehan S; Thomas ZM; Wright D; Stockdale L; Hamidi A; O'Shea MK; Dwivedi K; Behrens HM; Davenne T; Morton J; Vermaak S; Lawrie A; Moss P; McShane H
Vaccine; 2020 Jan; 38(4):779-789. PubMed ID: 31735500
[TBL] [Abstract][Full Text] [Related]
17. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
Spertini F; Audran R; Chakour R; Karoui O; Steiner-Monard V; Thierry AC; Mayor CE; Rettby N; Jaton K; Vallotton L; Lazor-Blanchet C; Doce J; Puentes E; Marinova D; Aguilo N; Martin C
Lancet Respir Med; 2015 Dec; 3(12):953-62. PubMed ID: 26598141
[TBL] [Abstract][Full Text] [Related]
18. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity.
Hoft DF; Blazevic A; Stanley J; Landry B; Sizemore D; Kpamegan E; Gearhart J; Scott A; Kik S; Pau MG; Goudsmit J; McClain JB; Sadoff J
Vaccine; 2012 Mar; 30(12):2098-108. PubMed ID: 22296955
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.
Idoko OT; Owolabi OA; Owiafe PK; Moris P; Odutola A; Bollaerts A; Ogundare E; Jongert E; Demoitié MA; Ofori-Anyinam O; Ota MO
Tuberculosis (Edinb); 2014 Dec; 94(6):564-78. PubMed ID: 25305000
[TBL] [Abstract][Full Text] [Related]
20. The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial.
Ritz N; Dutta B; Donath S; Casalaz D; Connell TG; Tebruegge M; Robins-Browne R; Hanekom WA; Britton WJ; Curtis N
Am J Respir Crit Care Med; 2012 Jan; 185(2):213-22. PubMed ID: 22071384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]